Beate Kern, NanoTemper Technologies
Screening, identifying and selecting drug candidates can be some of the most complex hurdles that drug discovery scientists face in their research. The sheer throughput as well as the diverse complexity of samples versus the demands to get a precise result in a timely-manner, can be challenging. Used together, Prometheus and Dianthus systems from NanoTemper address the throughput and characterization challenges to provide precise information about protein hits from discovery to formulation steps in a screen.
Prometheus precisely characterizes conformational and colloidal stability of proteins. It does this in a label-free way, in any buffer and using only a few µL of sample. The platform can be automated, so hundreds to thousands of samples can be measured in a day.
Dianthus identifies hits for any target type in any buffer or bioliquid directly in solution, measures a wide range of binding affinities all by consuming the smallest amount of your target and library compounds. It can be integrated into any automated solution, allowing the determination of 1500 Kd s in 24 hours.
We will share examples of how using both, Prometheus and Dianthus, enables researchers to more efficiently and effectively screen and characterize their drug discovery hits.
